The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

ARID3B  -  AT rich interactive domain 3B (BRIGHT-like)

Homo sapiens

Synonyms: ARID domain-containing protein 3B, AT-rich interactive domain-containing protein 3B, BDP, Bright and dead ringer protein, Bright-like protein, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ARID3B

  • CONCLUSIONS: It is concluded that, in the topical treatment of active distal ulcerative colitis, BDP 3 mg enemas are as efficacious as PP 30 mg enemas, without interference with the HPA axis [1].
  • RESULTS: FPANS 200 micrograms once or twice daily was significantly better than placebo but not better than BDP in relieving the nasal symptoms of rhinitis [2].
  • BDP and cisPt (0.2-20 microM) dose-dependently inhibited DNA synthesis in L1210 murine leukemia cells, DU-145 prostate cancer cells, A549 lung carcinoma cells, and MCF-7 breast cancer cells, as judged by measuring [(3)H]-thymidine incorporation [3].
  • Both cyclosporine and BDP improved the eczema [4].
  • The treatment of bronchial asthma with QVAR (hydrofluoroalkane-134a BDP; 3M Pharmaceuticals, St. Paul, MN, USA) is usually conducted without an inhalation assistance device [5].

Psychiatry related information on ARID3B

  • Our findings contribute a further argument to the hypothesis of low serotonergic neurotransmission in BDP and may point to a trait character of impulsiveness in this personality disorder [6].
  • Concordance of MMPI profile for BDP confirmed the findings of four previous studies [7].
  • RESULTS: There were significant improvements in HRQoL with FP on four of the eight dimensions on the SF-36 (i.e. physical functioning, general health, role-emotional, and mental health), while there were no significant improvements in HRQoL in the BDP/BUD group [8].

High impact information on ARID3B

  • RESULTS: There was a 0.9 (95% confidence interval, 0.5-1.2) doubling dose improvement in methacholine PD20 comparing asthma before versus after DPI-BDP [9].
  • Suppression of plasma and urinary cortisol and serum osteocalcin levels occurred with DPI-BDP, but values returned to baseline levels within 1 month of HFA-BDP or FP-SM administration [9].
  • Chlorofluorocarbon-beclomethasone dipropionate (CFC-BDP) MDIs deliver more than 90% of the drug in the oropharynx and less than 10% in the lungs [10].
  • BACKGROUND: We compared the effect of nasal azelastine (0.56 mg/day), nasal beclomethasone dipropionate (BDP, 200 micrograms/day) and matched placebo on seasonal symptoms, nasal cytology, and the increase in bronchial responsiveness occurring during pollen season in a group of subjects with history of allergic rhinitis to grass pollens only [11].
  • Neither azelastine nor BDP protected against the increase in bronchial responsiveness to methacholine occurring during the pollen season [11].

Chemical compound and disease context of ARID3B


Biological context of ARID3B

  • RESULTS: Inhaled BDP significantly improved asthma symptom scores and forced expiratory volume in 1 s, and decreased blood eosinophil counts, total serum IgE levels and specific IgE antibodies to house dust mite and cedar [14].
  • Activity of the complex is controlled by covalent modification with phosphorylation of its branched-chain alpha-ketoacid dehydrogenase subunits by a specific kinase [branched-chain kinase (BDK)] causing inactivation and dephosphorylation by a specific phosphatase [branched-chain phosphatase (BDP)] causing activation [15].
  • A fourth treatment arm administering BDP 84, eight oral inhalations bid (HD BDP 84; 1,344 microg/d) was also included to determine whether a dose-response relationship could be demonstrated [16].
  • PATIENTS AND DESIGN: Controlled observational study employing 21 patients on inhaled BDP recruited from general practice, with minimal past and no present exposure to other corticosteroids, and 21 age and gender-matched controls [17].
  • The rank order of potency was MF (average IC50 0.01 nM) > BDP (4.0 nM) > HC (250 nM) [18].

Anatomical context of ARID3B

  • BDP, but not azelastine, treatment significantly reduced the percent of eosinophils recovered in nasal lavage (p < 0.05) [11].
  • However, BDP treatment had a marked effect in reducing the expression of the activation markers CD25 and HLA-DR (p < 0.02) in T cells recovered by BAL in which these markers were upregulated [19].
  • Erythrocyte total glutathione levels significantly decreased after 6 weeks treatment with BDP (from 7.0+/-0.4 to 6.6+/-0.3 micromol x g Hb(-1) (p = 0.04)) [20].
  • OBJECTIVE: In this study we compared the effect of hydrocortisone (HC), beclomethasone (BDP), and mometasone (MF) on interleukin (IL)-4 and IL-5 secretion by aeroallergen-specific T-helper type 2 cells (Th2) and proliferation of PBMC from atopic donors [18].
  • After the first sputum induction, inhaled beclomethasone dipropionate (BDP 800 microg/day) was administered to asthmatic patients for 8 weeks, and sputum induction was repeated [21].

Associations of ARID3B with chemical compounds

  • Twice-daily regimens of inhaled steroids over a dose range of 200 to 1600 micrograms BDP or the equivalent should enable most patients with chronic asthma to receive effective therapy without recourse to potentially more toxic oral bronchodilator or steroid therapy [22].
  • METHODS: The study was completed by nine subjects in the azelastine group, 13 subjects in the BDP group, and 13 subjects in the placebo group [11].
  • Nasal therapy with azelastine and BDP did not block the increase in bronchial responsiveness to methacholine caused by seasonal allergen exposure [11].
  • METHODS--Timed urine collections and 09.00 hour plasma cortisol levels were obtained from 12 normal volunteers receiving inhaled placebo, beclomethasone (BDP) 800 or 2000 micrograms/day [23].
  • Moreover, a single high dose of BDP/formoterol (1000 microg/60 microg) was generally well tolerated in patients with asthma [24].

Analytical, diagnostic and therapeutic context of ARID3B


  1. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Campieri, M., Cottone, M., Miglio, F., Manenti, F., Astegiano, M., D'Arienzo, A., Manguso, F., D'Albasio, G., Bonanomi, A., Galeazzi, R., Orlando, A., Castiglione, G.N., Gionchetti, P. Aliment. Pharmacol. Ther. (1998) [Pubmed]
  2. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Scadding, G.K., Lund, V.J., Jacques, L.A., Richards, D.H. Clin. Exp. Allergy (1995) [Pubmed]
  3. Borato-1,2-diaminocyclohexane platinum (II), a novel anti-tumor drug. Dibas, A., Howard, J., Anwar, S., Stewart, D., Khan, A. Biochem. Biophys. Res. Commun. (2000) [Pubmed]
  4. Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Granlund, H., Erkko, P., Eriksson, E., Reitamo, S. Acta Derm. Venereol. (1996) [Pubmed]
  5. Usefulness of QVARTM for the Treatment of Bronchial Asthma-With and Without Use of an Inhalation Device. Tohda, Y., Tsuji, F., Kubo, H., Haraguchi, R., Iwanaga, T. The Journal of asthma : official journal of the Association for the Care of Asthma. (2006) [Pubmed]
  6. Enhanced intensity dependence as a marker of low serotonergic neurotransmission in borderline personality disorder. Norra, C., Mrazek, M., Tuchtenhagen, F., Gobbelé, R., Buchner, H., Sass, H., Herpertz, S.C. Journal of psychiatric research. (2003) [Pubmed]
  7. Borderline personality disorder: replication of MMPI profiles. Resnick, R.J., Goldberg, S.C., Schulz, S.C., Schulz, P.M., Hamer, R.M., Friedel, R.O. Journal of clinical psychology. (1988) [Pubmed]
  8. Improvement in health-related quality of life with fluticasone propionate compared with budesonide or beclomethasone dipropionate in adults with severe asthma. Rutherford, C., Mills, R., Gibson, P.G., Price, M.J. Respirology (2003) [Pubmed]
  9. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. Fowler, S.J., Currie, G.P., Lipworth, B.J. J. Allergy Clin. Immunol. (2002) [Pubmed]
  10. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. Leach, C. J. Allergy Clin. Immunol. (1999) [Pubmed]
  11. Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic rhinitis in response to grass pollens. Pelucchi, A., Chiapparino, A., Mastropasqua, B., Marazzini, L., Hernandez, A., Foresi, A. J. Allergy Clin. Immunol. (1995) [Pubmed]
  12. Treatment with inhaled steroids in asthma and chronic bronchitis: long-term compliance and inhaler technique. Dompeling, E., Van Grunsven, P.M., Van Schayck, C.P., Folgering, H., Molema, J., Van Weel, C. Family practice. (1992) [Pubmed]
  13. The effect of beclomethasone diproprionate on bronchial hyperreactivity. Clarke, P.S. The Journal of asthma : official journal of the Association for the Care of Asthma. (1982) [Pubmed]
  14. Effects of inhaled beclomethasone dipropionate on serum IgE levels and clinical symptoms in atopic asthma. Ohrui, T., Funayama, T., Sekizawa, K., Yamaya, M., Sasaki, H. Clin. Exp. Allergy (1999) [Pubmed]
  15. Overview of the molecular and biochemical basis of branched-chain amino acid catabolism. Harris, R.A., Joshi, M., Jeoung, N.H., Obayashi, M. J. Nutr. (2005) [Pubmed]
  16. A comparison of double-strength beclomethasone dipropionate (84 microg) MDI with beclomethasone dipropionate (42 microg) MDI in the treatment of asthma. Nathan, R.A., Nolop, K.B., Cuss, F.M., Lorber, R.R. Chest (1997) [Pubmed]
  17. Inhaled beclomethasone dipropionate suppresses the hypothalamo-pituitary-adrenal axis in a dose dependent manner. Grebe, S.K., Feek, C.M., Durham, J.A., Kljakovic, M., Cooke, R.R. Clin. Endocrinol. (Oxf) (1997) [Pubmed]
  18. Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines. Crocker, I.C., Church, M.K., Newton, S., Townley, R.G. Ann. Allergy Asthma Immunol. (1998) [Pubmed]
  19. Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma. Wilson, J.W., Djukanović, R., Howarth, P.H., Holgate, S.T. Am. J. Respir. Crit. Care Med. (1994) [Pubmed]
  20. Changes in levels of catalase and glutathione in erythrocytes of patients with stable asthma, treated with beclomethasone dipropionate. Pennings, H.J., Borm, P.J., Evelo, C.T., Wouters, E.F. Eur. Respir. J. (1999) [Pubmed]
  21. Potential mechanisms of improvement of airway hyperresponsiveness by inhaled corticosteroid therapy in asthmatic patients. Nomura, S., Kanazawa, H., Asai, K., Nomura, N., Hirata, K., Yoshikawa, J. The Journal of asthma : official journal of the Association for the Care of Asthma. (2006) [Pubmed]
  22. Inhaled corticosteroid therapy: a substitute for theophylline as well as prednisolone? Clark, T.J. J. Allergy Clin. Immunol. (1985) [Pubmed]
  23. Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. McIntyre, H.D., Mitchell, C.A., Bowler, S.D., Armstrong, J.G., Wooler, J.A., Cowley, D.M. Thorax (1995) [Pubmed]
  24. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Dhillon, S., Keating, G.M. Drugs (2006) [Pubmed]
  25. In vitro effect of beclomethasone dipropionate and flunisolide on the mobility of human nasal cilia. Stafanger, G. Allergy (1987) [Pubmed]
  26. Effect of beclomethasone dipropionate on the bronchial responsiveness to propranolol in asthmatics. Carpentiere, G., Castello, F., Marino, S. Chest (1990) [Pubmed]
  27. Injectable atypical antipsychotics for agitation in borderline personality disorder. Pascual, J.C., Madre, M., Soler, J., Barrachina, J., Campins, M.J., Alvarez, E., Pérez, V. Pharmacopsychiatry (2006) [Pubmed]
WikiGenes - Universities